Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ZB001 for injection
ZB001 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ZB001 for injection | EXPERIMENTAL | Treat different dose cohorts with four intravenous injections of ZB001 |
| Name | Type | Description |
|---|---|---|
| ZB001 for injection | DRUG | Dose Cohort1 (3 mg/kg) ZB001 four IV injections |
Inclusion Criteria: 1. Male or female adults, 18 years of age or older 2. Clinical diagnosis of Graves' ophthalmopathy and CAS evaluation of eyes under study ≥ 4 points (7 points in total) 3. Moderate-to-severe active thyroid-associated ophthalmopathy (i.e., severely affects daily life): exophthalm...
ZB001 is an investigational small molecule being developed by Zenas BioPharma, Inc. for the treatment of thyroid eye disease, an endocrine condition. It is in Phase 1 clinical development and has been studied in a completed Phase 1 trial in Chinese patients. ZB001 is also known as ZB001 for injection.
ZB001 is being developed as a treatment for thyroid eye disease, an endocrine condition affecting the tissues around the eyes. It is an investigational small molecule in Phase 1 development. Zenas BioPharma, Inc. is evaluating ZB001 for this indication, and a Phase 1 study in Chinese patients has been completed.
ZB001 is being developed by Zenas BioPharma, Inc., which trades under the ticker ZBIO. The company is advancing ZB001 as an investigational small molecule for thyroid eye disease. Zenas BioPharma conducted a completed Phase 1 trial of ZB001 in Chinese patients with thyroid eye disease.
ZB001 is in Phase 1 clinical development. It is an investigational small molecule and has not been approved for any indication. One Phase 1 trial of ZB001 has been completed, and no active trials are currently listed. The completed study enrolled 17 patients with thyroid eye disease in China.
ZB001 has been studied in one completed Phase 1 trial, NCT05776121, titled Study of ZB001 in Chinese Patients With Thyroid Eye Disease. The trial enrolled 17 patients in China, was uncontrolled, and was not randomized or double blinded. No active trials of ZB001 are currently listed.
Yes, ZB001 for injection is another name for ZB001. Both refer to the same investigational small molecule developed by Zenas BioPharma, Inc. for thyroid eye disease. ZB001 is in Phase 1 development and has completed one Phase 1 trial in Chinese patients.